NEWSROOM | Galderma

Beyond trends: equipping the aesthetics community for what’s NEXT

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

CHMP recommends approval of Galderma’s nemolizumab for moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union

Galderma’s phase III OLYMPIA 1 data published in JAMA Dermatology demonstrate that nemolizumab improves core signs and symptoms of prurigo nodularis

Celebrating 25 years of Sculptra®: new data and recent approval in China cements Galderma’s leadership in regenerative biostimulation

Galderma brings together over 650 healthcare professionals from Asia-Pacific to elevate knowledge of future aesthetic trends

Galderma delivers record net sales of 3.259 B USD in the first nine months of 2024, demonstrates significant innovation progress, confirms and narrows its full year net sales guidance

ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

ASDS 2024: Galderma presents data on RelabotulinumtoxinA and Sculptra®

EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentations

EADV 2024: scientific presentations supported by Galderma

Galderma reaffirms its leadership in dermatology with extensive presence at EADV 2024

Identifying unmet patient needs on World Atopic Eczema Day